|
市場調查報告書
第一三共：製藥企業分析報告
Daiichi Sankyo: Pipeline * Products * Performance * Potential
|
第一三共：製藥企業分析報告 是由出版商Espicom Business Intelligence在2009年10月所出版的。
這份英文市場調查報告書包含Pages: 98 價格從美金1040起跳。
以製藥、醫療器材相關調查公司中提供具權威情報之Espicom Business Intelligence（總公司：英國）發行了針對第一三共股份有限公司進行的業務分析報告書"Daiichi Sankyo - Prospects to 2010"。
本報告書為，匯整第一三共股份有限公司之企業策略、產品組合、財務實績、從2000年至2010年為止之銷售數據等，並以下列形式闡述。
實施概要
- 簡介
- 2005年之財務實績
- 企業策略
- 產品／R&D概要
- 結論
產品組合／R&D
- 心血管
- 代謝性疾病
- 傳染性疾病
- 癌症
- 免疫疾病／過敏
- 骨／關節
- 其他
附錄
- 財務實績
- 主要合作
- 基礎設施
- 關係企業／合資企業
- 產品索引
Abstract
Daiichi Sankyo's core strategy is to become a Japanese "Global Pharma
Innovator". This report provides a full review of the company's activities
together with sales forecasts for key products to 2010.
For the nine months ended 31st December 2005, Daiichi Sankyo's net sales were
¥704,039 million. Operating income was ¥134,294 million and net income was
¥80,992 million. Research and development expenditure was ¥113,371 million and
pharmaceutical sales were ¥606,349 million.
Key products
Daiichi Sankyo intends to maximise the value of its existing leading products,
beyond what could have been achieved by the companies separately. For example:
- Daiichi Sankyo is undertaking life-cycle management of the
antihypertensive, Olmetec/Benicar, which is one of the companies main
growth drivers. Since its introduction in a number of markets, sales and
market share are increasing.
- The future growth of the anti-infective Cravit is expected to be
strong due to life-cycle management efforts.
- In fiscal 2005, sales of the antihypertensive, Calblock, increased
by 400%, to reach ¥3,000 million and are forecast to exceed ¥10 billion in
Japan.
Overseas pharmaceutical sales were negatively affected by the expiration of
the patent in certain European countries for pravastatin and increasing
competition faced by that product in the US, which weakened sales of bulk
pravastatin. However, sales of olmesartan and levofloxacin were strong.
Major Products Forecast to 2010
- Cravit (Antibacterial)
- Omnipaque (Contrast agent)
- Panaldine (Cardiovascular)
- Artist (Cardiovascular)
- Sunrythm (Cardiovascular)
- Zyrtec (Anti-inflammatory)
- Mevalotin (Cardiovascular)
- Loxonin (Anti-infective)
- Remacin (Haematological)
- Acecol (Cardiovascular)
- Banan (Antibacterial)
- Espo (Haematological)
- Carbenin (Antibacterial)
- Gran (Anticancer)
- Alesion (Anti-allergenic)
- Olmetec (Cardiovascular)
Table of Contents
Latest Results
EXECUTIVE SUMMARY
- Introduction
- Financial Performance 2005
- Sales and Market Position
- Income
- Operating Income By Business Area - Daiichi
- Operating Income by Business Area - Daiichi
- Operating Income By Business Area - Sankyo
- Operating Income by Business Area - Sankyo
- Expenditure
- Capital Expenditure
- Capital Expenditure By Business Area - Daiichi
- Capital Expenditure by Business Area - Daiichi
- Capital Expenditure By Business Area - Sankyo
- Capital Expenditure by Business Area - Sankyo
- R&D Expenditure
- Divisional Performance
- Sales By Business Area - Daiichi
- Sales By Business Area - Daiichi
- Sales By Business Area - Sankyo
- Sales by Business Area - Sankyo
- Total Assets By Business Area - Daiichi
- Total Assets By Business Area - Daiichi
- Total Assets By Business Area - Sankyo
- Total Assets by Business Area - Sankyo
- Geographic Performance
- Sales By Destination - Sankyo
- Sales by Destination - Sankyo
- Sales By Origin - Daiichi
- Sales By Origin - Daiichi
- Sales By Origin - Sankyo
- Sales By Origin - Sankyo
- Operating Income By Geographical Area - Sankyo
- Total Assets By Geographical Area - Sankyo
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Employees
- Product/R&D Overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- Discontinued Products
- R&D Strategy
- R&D Pipeline Overview
- Discontinued R&D Projects
- Sales Forecast
- Sales of Major Products (2000A-2010E)
- Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- Top Selling Products, 2005
- R&D Pipeline - Japan
- Cardiovascular - Products
- Major Launched Products
- Acecol
- Sales
- Competitor Products
- Sales Forecast
- Acecol Sales (2000A-2010E)
- Artist
- Sales
- Competitor Products
- Sales Forecast
- Artist Sales (2000A-2010E)
- Calblock
- Coversyl (DW-7950)
- Sales
- Key Markets/Indications
- Clinical Trial Results
- HANP Injection
- Livalo
- Mevalotin/Pravachol
- Sales
- Key Markets/Indications
- Further Development
- Competitor Products
- Generic Competition
- Sales Forecast
- Mevalotin Sales (2000A-2010E)
- Olmetec/Benicar
- Sales
- Markets/Indications
- Further Development
- Competitor Products
- Sales Forecast
- Olmetec/Benicar Sales (2000A-2010E)
- Panaldine
- Sales
- Safety Issues
- Competitor Products
- Sales Forecast
- Panaldine Sales (2000A-2010E)
- Sunrythm
- Sales
- Competitor Products
- WelChol
- Sales
- Key Markets/Indications
- Further Development
- Clinical Trial Results
- Cardiovascular - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- Adenoscan
- CS-3030
- DU-176b
- DZ-697b
- HGF DNA plasmid
- KAI-9803
- Prasugrel (CS-747, LY640315)
- SUN N4057
- SUN N8075
- Cardiovascular - Summary
- Growth Potential
- Limiting Factors
- Metabolism - Products
- Major Launched Products
- Fastic
- Sales
- Markets/Indications
- Further Development
- Others
- Metabolism - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- CS-011
- CS-872
- CS-917 (R-132917)
- Fidarestat (SNK-860)
- SUN E7001
- Metabolism - Summary
- Growth Potential
- Limiting Factors
- Infection - Products
- Major Launched Products
- Banan
- Sales
- Key Markets/Indications
- Generic Competition
- Sales Forecast
- Banan Sales (2000A-2010E)
- Carbenin
- Carbenin Sales (2000A-2010E)
- Cravit
- Sales
- Key Markets/Indications
- Lawsuits/Generic Competition
- Sales Forecast
- Cravit Sales (2000A-2010E)
- Infection - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- Act-HIB (DF-098)
- CS-023
- CS-3955
- CS-758
- CS-8958 (R118958)
- DX-619
- Faropenem medoxomil
- Gracevit (DU-6859a)
- Infection - Summary
- Growth Potential
- Limiting Factors
- Cancer - Products
- Topotecin
- Key Markets/Indications
- Further Development
- Cancer - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- CS-706 (R-109339)
- CS-1008 (R-161460)
- CS-7017 (RS-5444)
- TZT-1027
- DJ-927
- Cancer - Summary
- Immunity and Allergy - Products
- Major Launched Products
- Alesion
- Alesion Sales (2000A-2010E)
- Zyrtec
- Sales
- Key Markets/Indications
- Competitor Products
- Sales Forecast
- Zyrtec Sales (2000A-2010E)
- Immunity and Allergy - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- CS-0777
- CS-502
- CS-712 (R-133663)
- CS-9507 (R-125224)
- DW-908e
- Xolair (omalizumab, IGE025)
- Immunity and Allergy - Summary
- Growth Potential
- Limiting Factors
- Bone and Joints - Products
- Major Launched Products
- Loxonin
- Sales
- Key Markets/Indications
- Further Development
- Competitor Products
- Sales Forecast
- Loxonin Sales (2000A-2010E)
- Mobic
- Bone and Joints - R&D
- R&D Pipeline - Japan
- OCIF (R-142440)
- SUN E3001
- Bone and Joints - Summary
- Other - Products
- Major Launched Products
- Feron
- Kremezin
- Omnipaque
- Omnipaque Sales (2000A-2010E)
- Zantac
- Zantac Sales (2000A-2010E)
- Others - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- CS-088
- CS-526 (R-105266)
- CS-801
- CS-1401E
- Dopascan
- DL-404
- Sonazoid
- SUN11031
- SUN0588r
- SUN-Y7017
- Urief
APPENDIX 1 - FINANCIAL PERFORMANCE
- Full Year Results - Proforma
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
- Full Year Results 2005 - Daiichi
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- Research Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
- Full Year Results 2005 - Sankyo
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
APPENDIX 2 - KEY AGREEMENTS
- A Menarini Industrie Farmaceutiche Riunte SrL
- Amersham Health
- AnGes MG Inc
- January 2001
- 9th April 2002
- Astellas Pharma Inc
- 2nd June 2003
- 27th August 2004
- BioMarin Pharmaceutical Inc
- 23rd November 2004
- 5th May 2005
- BioMimetic Pharmaceuticals Inc (BMP)
- Biota Holdings Limited
- Boehringer Ingelheim
- Cyclacel Limited
- Eli Lilly
- Forest Laboratories Inc
- GelTex Pharmaceuticals Inc
- GlaxoSmithKline
- 2nd November 2001
- 27th January 2003
- Kissei Pharmaceutical Co Ltd
- Kureha Chemical Industry Co Ltd
- Kyoto Pharmaceutical Industries Ltd
- Metabasis Therapeutics Inc
- 18th December 1997
- 11th January 1999
- 29th October 2002
- 8th April 2004
- Novartis
- Pfizer
- 18th May 1999
- 29th May 2000
- Pharmacopeia Inc
- 3rd February 2003
- 2nd December 2003
- Roche
- sanofi-aventis
- July 1993
- 13th February 2003
- 5th July 2005
- Sanwa Kagaku Kenkyusho
- Schering-Plough
- Suntory Ltd
- Teikoku Hormone Mfg Co Ltd
- Ube Industries Ltd
- University of Alabama
- Zeria Pharmaceutical Co Ltd
APPENDIX 3 - KEY PHARMACEUTICAL SUBSIDIARIES/JOINT VENTURES
- Subsidiaries
- Joint Ventures
APPENDIX 4 - PRODUCT INDEX
|
